Valuation
- Market cap
- 21,353,000
- Revenue TTM
- $0
- Net income TTM
- $-22,230,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 96,100
- Avg volume
- 329,474
- Day's range
- $0.80 – $0.95
- Shares out
- 24,014,000
- Stochastic %K
- 60%
- Beta
- 1.21
- Analysts
- Strong Sell
- Price target
- $10.25
Company profile
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric...
Show more
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 817 887 8455
- Website
- https://actuatetherapeutics.com
- Address
- 1751 River Run, Suite 400, Fort Worth, United States
Latest news
No headlines yet.
